A Phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer

Lynn G Feun, K. R. Reddy, Jose Yrizarry, Niramol Savaraj, J. J. Guerra, R. K. Purser, S. Waldman, Joe Levi, Frederick L Moffat, L. Morrell, Alan Livingstone, Bach Ardalan, Pasquale W Benedetto

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.

Original languageEnglish
Pages (from-to)405-410
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number5
StatePublished - Jan 1 1994

Fingerprint

Ethiodized Oil
Liver Neoplasms
Cisplatin
Hepatocellular Carcinoma
Liver
Melanoma
Serum
Hiccup
Pleural Effusion
Transaminases
Bilirubin
Ascites
Colonic Neoplasms
Abdominal Pain
Creatinine
Fever
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. / Feun, Lynn G; Reddy, K. R.; Yrizarry, Jose; Savaraj, Niramol; Guerra, J. J.; Purser, R. K.; Waldman, S.; Levi, Joe; Moffat, Frederick L; Morrell, L.; Livingstone, Alan; Ardalan, Bach; Benedetto, Pasquale W.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 5, 01.01.1994, p. 405-410.

Research output: Contribution to journalArticle

@article{730b5242f0924139a9bc93596fbb6566,
title = "A Phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer",
abstract = "Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.",
author = "Feun, {Lynn G} and Reddy, {K. R.} and Jose Yrizarry and Niramol Savaraj and Guerra, {J. J.} and Purser, {R. K.} and S. Waldman and Joe Levi and Moffat, {Frederick L} and L. Morrell and Alan Livingstone and Bach Ardalan and Benedetto, {Pasquale W}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "405--410",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A Phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer

AU - Feun, Lynn G

AU - Reddy, K. R.

AU - Yrizarry, Jose

AU - Savaraj, Niramol

AU - Guerra, J. J.

AU - Purser, R. K.

AU - Waldman, S.

AU - Levi, Joe

AU - Moffat, Frederick L

AU - Morrell, L.

AU - Livingstone, Alan

AU - Ardalan, Bach

AU - Benedetto, Pasquale W

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.

AB - Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.

UR - http://www.scopus.com/inward/record.url?scp=0028111676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028111676&partnerID=8YFLogxK

M3 - Article

C2 - 8092112

AN - SCOPUS:0028111676

VL - 17

SP - 405

EP - 410

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -